Complications of intravesical therapy

Complications of Urologic Surgery and Practice: Diagnosis, Prevention, and Management

Volumn , Issue , 2007, Pages 455-475

  O'Donnell, Michael A ^a   Maymí, José L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54049121151     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (183)

1. Haukaas S, Daehlin L, Maartmann-Moe H, et al. The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int 1999; 83: 957-963.
2. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68:549-553.
3. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86-91.
4. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004; 171:2186-2190.
5. Baselli EC, Greenberg RE. Maintenance therapy for superficial bladder cancer. Oncology (Williston Park) 2001; 15:85-88.
6. Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000; 53:676-880.
7. Highley MS, van Oosterom AT, Maes RA, et al. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999; 37:59-73.
8. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004; 15:858-862.
9. Bibby MC, McDermott BJ, Double JA, et al. Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours. Cancer Chemother Pharmacol 1987; 20:203-206.
10. Masters JR, McDermott BJ, Harland S, et al. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother Pharmacol 1996; 38:59-64.
11. Weaver D, Khare N, Haigh J, et al. The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture. Invest Urol 1980; 17:288-292.
12. Lunglmayr G, Czech K. Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. J Urol 1971; 106:72-74.
13. Veenema RJ, Dean AL Jr, Uson AC, Roberts M, Longo F. Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J Urol 1969; 101:711-715.
14. Jones HC, Swinney J. Thiotepa in the treatment of tumours of the bladder. Lancet 1961; 2:615-618.
15. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin N Am 1992; 19:529-539.
16. Silberberg JM, Zarrabi MH. Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature. J Urol 1987; 138:402-403.
17. Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162:1697-1701.
18. Homonnai TZ, Paz G, Servadio C. Sterilisation following instillation of thiotepa into the urinary bladder. Br J Urol 1982; 54:60.
19. Choe JM, Kirkemo AK, Sirls LT. Intravesical thiotepa-induced eosinophilic cystitis. Urology 1995; 46:729-731.
20. Treible DP, Skinner D, Kasimain D, et al. Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa. Urology 1987; 30:568-570.
21. Mukamel E, Glanz I, Nissenkorn I, Cytron S, Servadio C. Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder. J Urol 1982; 127:245-246.
22. Medical Research Council. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol 1985; 57:680-685.
23. Zincke H, Utz DC, Taylor WF, et al. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 1983; 129:505-509.
24. Zincke H, Benson RC Jr, Hilton JF, et al. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. J Urol 1985; 134:1110-1114.
25. Burnand KG, Boyd PJ, Mayo ME, et al. Single dose intravesical thiotepa as an adjuvant to cystodia-thermy in the treatment of transitional cell bladder carcinoma. Br J Urol 1976; 48:55-59.
26. Gavrell GJ, Lewis RW, Meehan WL, Leblanc GA. Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 1978; 120: 410-411.
27. Xu BH, Gupta V, Singh SV. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. Br J Cancer 1994; 69:242-246.
28. Badalament RA, Farah RN. Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol 1997; 13:335-341.
29. Iyer VN, Szybalski W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci U S A 1963; 50:355-362.
30. Lown JW. The molecular mechanism of antitumor action of the mitomycins. In: Carter SK, Crooke ST, eds. Mitomycin C: Current Status and New Developments. Orlando, FL: Academic Press, 1979:5.
31. Dalton JT, Wientjes MG, Badalament RA, et al. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991; 51:5144-5152.
32. De Bruijn EA, Sleeboom HP, van Helsdingen PJ, et al. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 1992; 51:359-364.
33. van Helsdingen PJ, Rikken CH, Sleeboom HP, et al. Mitomycin C resorption following repeated intravesical instillations using different instillation times. Urol Int 1988; 43:42-46.
34. Wajsman Z, Dhafir RA, Pfeffer M, et al. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. J Urol 1984; 132:30-33.
35. Schmidbauer CP, Porpaczy P, Georgopoulos A, et al. Absorption of doxorubicin-hydrochloride and mitomycin-C after instillation into noninfected and infected bladders of dogs. J Urol 1984; 131: 818-821.
36. Au JL, Badalament RA, Wientjes MG, et al; International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001; 93:597-604.
37. Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C phar-macokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001; 52:273-278.
38. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170:777-782.
39. Crooke ST, Henderson M, Samson M, et al. Phase I study of oral mitomycin C. Cancer Treat Rep 1976; 60:1633-1636.
40. Zein TA, Friedberg N, Kim H. Bone marrow suppression after intravesical mitomycin C treatment. J Urol 1986; 136:459-460.
41. Racioppi M, Porreca A, Foschi N, et al. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int 2005; 75:373-375.
42. Brady JD, Assimos DG, Jordan GH. Urethral slough: a rare and previously unreported complication of intravesical mitomycin. J Urol 2000; 164:1305.
43. Neulander EZ, Lismer L, Kaneti J. Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c. J Urol 2000; 164:1306.
44. Eijsten A, Knonagel H, Hotz E, et al. Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Br J Urol 1990; 66:386-388.
45. Clark T, Chang SS, Cookson MS. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol 2002; 167:1795.
46. Jauhiainen K, Sotarauta M, Permi J, et al. Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. Eur Urol 1986; 12:32-37.
47. de Groot AC, Conemans JM. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermatitis 1991; 24:201-209.
48. Colver GB, Inglis JA, McVittie E, et al. Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction? Br J Dermatol 1990; 122:217-224.
49. Rao S, Cunningham D, Price T, et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004; 91:839-843.
50. DeFuria MD, Bracken RB, Johnson DE, et al. Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep 1980; 64:225-230.
51. Sonneveld P, Kurth KH, Hagemeyer A, et al. Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma. Cancer 1990; 65:23-25.
52. Llopis M, Moreno J, Botella R, et al. Incrusted cystitis after intravesical mitomycin C treatment. Acta Urol Belg 1993; 61:21-23.
53. Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intra-vesical mitomycin C instillation. Eur Urol 2003; 43:711-712.
54. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155:1233-1238.
55. Solsona E, Iborra I, Ricos JV, et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120-1123.
56. Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; 153:934-941.
57. Carter SK. Adriamycin-a review. J Natl Cancer Inst 1975; 55:1265-1274.
58. Triton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982; 217:248-250.
59. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000;27:125-135.
60. Wientjes MG, Badalament RA, Au JL. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 1996; 37:539-546.
61. Nagakura K, Takao M, Odajima K, et al. Serum uptake of doxorubicin intravesically administered soon after transurethral resection of bladder carcinoma. Hinyokika Kiyo 1989; 35:1509-1512.
62. Crawford ED, McKenzie D, Mansson W, et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. J Urol 1986; 136:668-669.
63. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149:749-752.
64. Marchetti A, Wang L, Magar R, et al. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000; 22:422-438.
65. Yoshimura A, Ogawa A, Wajiki M, et al. Chemical pericystitis: a rare complication of intravesical doxorubicin. J Urol 1986; 135:1237-1239.
66. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 2004; 46: 336-338.
67. Markman M, Homesley H, Norberts DA, et al. Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecol Oncol 1996; 61:90-93.
68. Matsumura Y, Tsushima T, Ozaki Y, et al. Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors. Cancer Chemother Pharmacol 1986; 16:176-177.
69. Burk K, Kurth KH, Newling D. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog Clin Biol Res 1989; 303:423-434.
70. Cumming JA, Kirk D, Newling DW, et al. A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. Eur Urol 1990; 17:20-22.
71. Kurth K, Vijgh WJ, ten Kate F, et al. Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J Urol 1991; 146:1508-1512.
72. Ali-el-Dein B, Nabeeh A, el-Baz M, et al. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997; 79:731-735.
73. Ali-el-Dein B, el-Baz M, Aly AN, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997; 158:68-73.
74. Eto H, Oka Y, Ueno K, et al. Comparison of the prophylactic usefulness of epirubicin and doxo-rubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol 1994; 35 (Suppl):S46-S51.
75. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluo-roacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997; 49:471-475.
76. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 2000; 56:232-235.
77. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761-767.
78. Newling DW, Hetherington J, Sundaram SK, et al. The use of valrubicin for the chemoresection of superficial bladder cancer-a marker lesion study. Eur Urol 2001; 39:643-647.
79. Hendricksen K, Witjes JA. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 2006; 16:361-366.
80. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 1990; 50:4417-4422.
81. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gem-citabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
82. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
83. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
84. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729-2734.
85. Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21:697-703.
86. De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93:491-494.
87. Palou J, Carcas A, Segarra J, et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 2004; 172:485-488.
88. Witjes JA, van der Heijden AG, Vriesema JL, et al. Intravesical gemcitabine: a phase 1 and pharmaco-kinetic study. Eur Urol 2004; 45:182-186.
89. De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93:491-494.
90. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65:65-69.
91. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-291.
92. de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998; 78:1342-1345.
93. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10:1385-1388.
94. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002; 86:326-330.
95. Pectasides D, Visvikis A, Aspropotamitis A, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 2000; 36:74-79.
96. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006; 24:3075-3080.
97. Stanford BL, Shah SR, Ballard EE, et al. A randomized trial assessing the utility of a test-dose program with taxanes. Curr Med Res Opin 2005; 21:1611-1616.
98. Masson P, Murphy AM, Goetzl MA, et al. Long-term follow up of intravesical docetaxel for the treatment of superficial bladder cancer resistant to standard intravesical therapy. J Urol 2006; 175(Suppl. 4):273, abstract no. 846.
99. Robinson MR, Shetty MB, Richards B, et al. Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. J Urol 1977; 118:972-973.
100. Kurth KH, Schroder FH, Tunn U, et al. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 1984; 132:258-262.
101. Ricos Torrent JV, Monros Lliso JL, Iborra Juan I, et al. Mitoxantrone (MTX) versus mitomycin C (MMC) in the ablative treatment of Ta, T1 superficial bladder tumors. Phase III, randomized prospective study. Arch Esp Urol 1992; 45:647-652.
102. Huang JS, Chen WH, Lin CC, et al. A randomized trial comparing intravesical instillations of mito-xantrone and doxorubicin in patients with superficial bladder cancer. Chang Gung Med J 2003; 26:91-97.
103. Papatsoris AG, Deliveliotis C, Giannopoulos A, et al. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 2004; 72:284-291.
104. Flamm J, Donner G, Oberleitner S, et al. Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. Eur J Cancer 1995; 31A:143-146.
105. Yaman LS, Yurdakul T, Zissis NP, et al. Intravesical mitoxantrone for superficial bladder tumors. Anticancer Drugs 1994; 5:95-98.
106. Stewart DJ, Green R, Futter N, et al. Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors. J Urol 1990; 143:714-716.
107. Serretta V, Corselli G, Pavone C, et al. Intravesical mitoxantrone in superficial bladder tumours (Ta-T1). Eur J Cancer 1993; 29A:1899-1900.
108. Blumenreich MS, Needles B, Yagoda A, et al. Intravesical cisplatin for superficial bladder tumors. Cancer 1982; 50:863-865.
109. Bouffioux C, Denis L, Oosterlinck W, et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 1992; 148:297-301.
110. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24:767-779.
111. Sternberg CN, Yagoda A, Bander NH, et al. Phase I/II trial of intravesical methotrexate for superficial bladder tumors. Cancer Chemother Pharmacol 1986; 18:265-269.
112. Sekine H, Ohya K, Kojima SI, et al. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol 2001; 8:483-486.
113. Fukui I, Sekine H, Kihara K, et al. Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors. Cancer Chemother Pharmacol 1987; 20(Suppl):S52-S55.
114. Yoshida O, Miyakawa M, Watanabe H, et al. Study of combination chemotherapy with cytosine arabi-noside in the intravesical treatment of superficial bladder tumors. Hinyokika Kiyo 1983; 29: 357-364.
115. Kinoshita N, Tochigi H, Yanagawa M, et al. Clinical study of intravesical instillation therapy of superficial bladder tumor-combination therapy of mitomycin C, adriamycin, peplomycin and cytosine arabinoside. Hinyokika Kiyo 1990; 36:257-263.
116. Sakamoto N, Naito S, Kumazawa J, et al.; Kyushu University Urological Oncology Group. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urol 2001; 8:212-216.
117. Maymi JL, Saltsgaver N, O'Donnell MA. Intravsical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 2006; 175(Suppl. 4):271, abstract no. 840.
118. Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol 1999; 161:1133-1135.
119. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992; 19:565-572.
120. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
121. Bohle A, Balck F, von Weitersheim J, et al. The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 1996; 155:1221-1226.
122. Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001; 57:883-888.
123. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95.
124. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44:429-434.
125. Hudson MA, Ratliff TL, Gillen DP, et al. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138: 295-298.
126. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immuno-therapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
127. Pagano F, Bassi P, Milani C, et al. Pathologic and structural changes in the bladder after BCG intra-vesical therapy in men. Prog Clin Biol Res 1989; 310:81-91.
128. Prescott S, James K, Hargreave TB, et al. Immunopathological effects of intravesical BCG therapy. Prog Clin Biol Res 1989; 310:93-105.
129. Mack D, Frick J. Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. Br J Urol 1996; 78:369-371.
130. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. EORTC Genito-Urinary Tract Cancer Group. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer GenitoUrinary Group Phase III Trial. Eur Urol 2003; 44:423-428.
131. Oates RD, Stilmant MM, Freedlund MC, et al. Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer. J Urol 1988; 140:751-754.
132. Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med 1997; 121:724-729.
133. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134:40-47.
134. Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982; 128:27-30.
135. Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J Urol 1999; 161:1568-1569.
136. Orihuela E, Herr HW, Pinsky CM, et al. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60:326-333.
137. Lamm DL, Steg A, Boccon-Gibod L, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989; 310:335-355.
138. Luftenegger W, Ackermann DK, Futterlieb A, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996; 155:483-487.
139. Lamm DL, Stogdill VD, Stogdill BJ, et al. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986; 135:272-274.
140. O'Donnell MA, Burns JA. Intravesical bacille Calmette-Guerin in the treatment and prophylaxis of urothelial bladder cancer. In: Droller MJ, ed. Atlas of Clinical Oncology: Urothelial Tumors. London: BC Decker, 2004:229-231.
141. Aikawa N. Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults. Nippon Geka Gakkai Zasshi 1996; 97:771-777.
142. Rival G, Garot D, Mercier E, et al. Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy. Presse Med 2006; 35:980-982.
143. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990; 144:1328-1330.
144. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intra-vesical bacillus Calmette-Guerin. J Urol 1990; 144:1331-1333.
145. Steg A, Leleu C, Debre B, et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 1989; 310:325-334.
146. DeHaven JI, Traynellis C, Riggs DR, et al. Antibiotic and steroid therapy of massive systemic bacillus Calmette- Guerin toxicity. J Urol 1992; 147:738-742.
147. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147:596-600.
148. Elkabani M, Greene JN, Vincent AL, et al. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Guerin treatments for bladder cancer. Cancer Control 2000; 7:476-181.
149. Kamphuis JT, Buiting AG, Misere JF, et al. BCG immunotherapy: be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations. Neth J Med 2001; 58:71-75.
150. Guerra CE, Betts RF, O'Keefe RJ, et al. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Guerin for bladder cancer. Clin Infect Dis 1998; 27:639-640.
151. Hakim S, Heaney JA, Heinz T, et al. Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report. J Urol 1993; 150:188-189.
152. Siskron FT, IV, Venable DD, Gonzalez E, et al. Granulomatous mass in a nonrefluxing renal unit after bacillus Calmette-Guerin therapy for bladder cancer. J Urol 1997; 158:882-883.
153. French CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacille calmette-guerin intravesical therapy. Rev Urol 2001; 3:36-38.
154. Durek C, Rusch-Gerdes S, Jocham D, et al. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37(Suppl 1):21-25.
155. Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guerin for bladder cancer [(clinical conference]). N Engl J Med 1998; 339:831-837.
156. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006; 26:481-488.
157. Hodish I, Ezra D, Gur H, et al. Reiter's syndrome after intravesical bacillus Calmette-Guerin therapy for bladder cancer. Isr Med Assoc J 2000; 2:240-241.
158. Yossepowitch O, Eggener SE, Bochner BH, et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 2006; 176:482-485.
159. Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003; 76:1514-1516.
160. Izes JK, Bihrle W III, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol 1993; 150:1498-1500.
161. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36:140-148.
162. van der Meijden AP. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995; 27(Suppl 1):23-28.
163. Takashi M, Wakai K, Ohno Y, et al. Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995; 27:723-733.
164. Martinez-Pineiro JA, Solsona E, Flores N, et al. Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO, Eur Urol 1995; 27(Suppl 1):13-18.
165. Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27(Suppl 1):19-22.
166. Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147:1256-1258.
167. Andius P, Fehrling M, Holmang S. Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005; 96:1290-1293.
168. Bassi P, Spinadin R, Carando R, et al. Modified induction course: a solution to side-effects? Eur Urol 2000; 37(Suppl 1):31-32.
169. van der Meijden AP, Brausi M, Zambon V, et al; Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476-481.
170. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, doubleblind, placebo controlled, multicenter study. J Urol 2006; 176:935-939.
171. Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 1988; 6:476-483.
172. Brown DH, Wagner TT, Bahnson RR. Interferons and bladder cancer. Urol Clin North Am 2000; 27:171-178.
173. Belldegrun AS, Franklin JR, O'Donnell MA, et al. Superficial bladder cancer: the role of interferonalpha. J Urol 1998; 159:1793-1801.
174. Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144:658-661.
175. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, et al. Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors. Eur Urol 1990; 18:201-203.
176. Portillo J, Martin B, Hernandez R, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997; 49:187-190.
177. Bartoletti R, Massimini G, Criscuolo D, et al. Interferon alfa 2a in superficial bladder cancer prophylaxis: toleration and long-term follow-up. A phase I-II study. Anticancer Res 1991; 11:2167-2170.
178. Malmstrom PU. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 2002; 89:681-686.
179. Papatsoris AG, Deliveliotis C, Giannopoulos A, et al. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 2004; 72:284-291.
180. da Silva FC, Furtado L, Reis M, et al. Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors. Portuguese Genito-Urinary Group. Eur Urol 1995; 28:291-296.
181. Giannakopoulos S, Gekas A, Alivizatos G, et al. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998; 82:829-834.
182. Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. Immunology 1999; 162:2399-2405.
183. O'Donnell MA, Lilli K, Leopold C. National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172:888-893.